fosifidancitinib   Click here for help

GtoPdb Ligand ID: 10637

Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: Fosifidancitinib is a Janus kinase (JAK) inhibitor that is claimed in Rigel Pharmaceuticals' patent WO2010085684A1 [1]. Strictly I-538 refers to the sodium salt but we represent the parent molecule in this entry. The chemical structure that was submitted to the WHO for the INN fosifidancitinib matches the structure of example I-538 (minus the sodium). Rigel declare two JAK inhibitor programmes on their pipeline webpage; one in partnership with Aclaris Therapeutics (ATI-501/ATI-502, oral and topical formulations respectively) for dermatological applications, and the second in partnership with AstraZeneca through which AZD0449 (R256) is being investigated as an inhalation asthma therapeutic. None of these investigational agents have published name to structure declarations.
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 8
Hydrogen bond donors 4
Rotatable bonds 8
Topological polar surface area 170.78
Molecular weight 505.12
XLogP 1.45
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES COc1cc(Nc2ncc(c(n2)Nc2ccc3c(c2)n(COP(=O)(O)O)c(=O)o3)C)cc(c1F)C
Isomeric SMILES COc1cc(Nc2ncc(c(n2)Nc2ccc3c(c2)n(COP(=O)(O)O)c(=O)o3)C)cc(c1F)C
InChI InChI=1S/C21H21FN5O7P/c1-11-6-14(8-17(32-3)18(11)22)25-20-23-9-12(2)19(26-20)24-13-4-5-16-15(7-13)27(21(28)34-16)10-33-35(29,30)31/h4-9H,10H2,1-3H3,(H2,29,30,31)(H2,23,24,25,26)
InChI Key JTUBTEKGIDQZMZ-UHFFFAOYSA-N
Bioactivity Comments
Example I-538 is reported to inhibit JAK3-mediated IL-2-induced proliferation of human primary T cells with a binned IC50 of 0.5-5 μM [1].